Bitchute odysee Telegram Feed

Who Will Stand Up for Women’s Health?

As regular readers will be aware, the FDA is poised to eliminate consumer access to compounded bioidentical hormones like estriol, progesterone, testosterone, and others. We’re working with our allies to mobilize members of Congress to take action on this critical women’s health issue. We need your help to get as many members to support our cause as we possibly can. Representatives Mark Pocan (D-WI) and Phil Roe (R-TN) are leading a Congressional letter asking the FDA to “consider the severely negative impact some of [the National Academies of Sciences, Engineering, and Medicine’s] recommendations would have on patients,” and requesting that consumer access to compounded bioidentical hormones be maintained. This is a critical issue, particularly for women. Many studies have shown that estriol offers many potential health benefits—for urinary tract and bone health, for example—without some of the dangers that accompany higher-potency estrogens, such as cancer. A ban would cause suffering for many, many women. But as we’ve written before, this is one among many attacks that, in our opinion, is meant to make it impossible for traditional compounding pharmacies to stay in business. The FDA still needs to go through the normal rulemaking process before estriol or other hormones are banned from compounding, but the time to act is now. We must get Congress on our side to try to reign in this agency.

Read More

Public Puts Pressure on the FDA to Not Ban Bioidentical Hormones

Thanks to your activism, the FDA has agreed to study bioidentical hormone replacement therapy. But the threat to hormones still looms. For months now, we’ve been telling you about the FDA’s attack on estriol, progesterone, and other bioidentical hormones that are made for individual patients at specialized pharmacies. Now, thanks to the activism of ANH members and other stakeholders, the agency has recently announced that they have asked the National Academies of Science, Engineering, and Medicine (NASEM) to conduct a study on bioidentical hormone replacement therapy (BHRT). This is a qualified victory: it shows that the FDA feels enough pressure from the public that they can’t ban bioidentical hormones outright. But the fight is far from over, and we must remain vigilant to ensure the future of bioidentical hormone replacement therapy (BHRT).

Read More

FDA Turns Its Back on Women with Menopause – Seeks to Restrict Access to Estriol

With their great safety profile and excellent health benefits, it isn’t surprising that one third of women who use hormone therapy choose estriol and other safe, effective, and natural bioidentical hormones to manage the symptoms of menopause. Unfortunately, the FDA is poised to remove access to these hormones and to leave ailing women with no other option but more dangerous alternatives. ANH-USA is leading the charge to protect these crucial hormones, but we need your help to enlist members of Congress to get the FDA to back off.

Read More

FDA Looks to Ban Bioidentical Hormones Like Estriol

Many millions of women depend on estriol. In 2008, the FDA – likely acting upon a petition it received from Wyeth Pharmaceuticals, the manufacturer of Premarin (an estrogen drug made from pregnant horse mares’ urine) – went after bioidentical hormones, particularly estriol. Thanks to ANH members and the wider natural health community, the FDA backed off. Now, they see an opportunity to remove estriol and other hormones by other means and we must once again mobilize to stop them.

Read More